| Offering Information |
| Expected Date | - |
| Proposed Exchange/Ticker |
Nasdaq: GNOM |
| Security Type |
Common Stock |
| Lead Underwriter |
CIBC World Markets Inc |
| Days In Registration |
198 |
| Date Filed |
15-Mar-2000 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2007) |
| Industry |
Pers/Bus/Rep Svc |
| Business Description |
Provide software products and services that enable pharmaceutical and biotechnology researchers to accelerate the drug discovery and development process |
| Revenue |
- |
| Net Income |
- |
| Shares Outstanding (post-offering) |
22.43M |
| CEO |
Teresa W. Ayers |
| Number of Employees |
81 |
|
| Original Filing Information |
| US |
| Shares Filed |
6.0M |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
6.0M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
966.0K |
| File Amount |
$96.0M |
| File Price Range |
$17.00 - $15.00 |
| File Mid Price |
$16.00 |
Current Filing Information
(Amended 27-Sep-2000) |
|
US |
|
Shares Filed |
5.0M |
| Secondary Shares Filed |
- |
| · As a Percent |
- |
| Primary Shares Filed |
5.0M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
- |
| File Amount |
$85.0M |
| · % Change from Original |
-11.46 |
| File Price Range |
$18.00 - $16.00 |
| File Mid Price |
$17.00 |
|
